Some studies presented at the ESMO Virtual Congress 2020 also show promise in addressing unmet needs in NETs, while a survey reveals delays in diagnosis or misdiagnosis are still common

Updates from three large global registries confirm that cancer is an independent adverse factor in people infected with coronavirus

The LungART trial provides conclusive evidence that mediastinal post-operative radiotherapy should not be used routinely in these patients, and that radical surgery can remain a single local modality, to be followed by a watch-and-wait strategy 

Innovations focussing on the macrophage compartment with MK-4830 and on T-cell co-stimulation with PRS-343 demonstrate the continued benefits of translational research in oncology

Studies show mixed results from combination therapies with osimertinib plus bevacizumab, and monotherapies with tarloxotinib or patritumab deruxtecan

Data presented at ESMO Virtual Congress 2020 reported on safety profiles of some MET inhibitors when combined with tyrosine kinase inhibitors and encouraging response rates in patients with non-small-cell lung cancer with MET exon 14 skipping mutations

First results from the LEAP-005 study show pretreated advanced cancers respond to the combination treatment

In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

[5:08 PM] Cinzia POZZI - ESMOchange the subtitle into: In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

Breaking data from the IMpassion031 trial provides further evidence to support a role for immunotherapy in early-stage triple negative breast cancer (TNBC).

The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib